Apotex acquires US rights to PROVIGIL and NUVIGIL

PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy

Apotex, the largest Canadian-based pharmaceutical company, announced that its affiliate Nuvo Pharmaceuticals (Ireland) DAC has acquired the United States rights to PROVIGIL (modafinil) and NUVIGIL (armodafinil).

PROVIGIL and NUVIGIL become the latest branded medicines to be sold in the United States within the Apotex Group’s diversified global portfolio of more than 550 generic and branded prescription, over the counter and biosimilar product families across all major therapeutic areas.

PROVIGIL and NUVIGIL each improve wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift work sleep disorder, and are prescribed by psychiatrists, endocrinologists, internists, sleep specialists, and primary care physicians.

“Acquiring the US rights to PROVIGIL and NUVIGIL marks a strategic milestone for Apotex and a significant initial step in growing our US specialty business, building upon the recent achievement of similar specialty transactions in Canada and advancing our Journey of Health growth strategy,” said Allan Oberman, Apotex’s President & CEO. “These acquisitions further reinforce our long-term commitment to improving patient care and continuing to expand our presence in the US.”

“PROVIGIL and NUVIGIL address critical needs for patients experiencing excessive sleepiness. Leveraging our world-class commercial team, established distribution networks, and expertise in the US market, we are well-positioned to ensure these medications continue to reach patients effectively,” said Christine Baeder, President of Apotex Corp., Apotex’s US affiliate.

PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder. More information on PROVIGIL is available here.